← Back to Screener
Anika Therapeutics Inc (ANIK)
Price$15.82
Favorite Metrics
Price vs S&P 500 (26W)66.96%
Price vs S&P 500 (4W)2.72%
Market Capitalization$213.74M
All Metrics
P/CF (Annual)19.10x
Book Value / Share (Quarterly)$10.33
P/TBV (Annual)0.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-10.28%
Cash Flow / Share (Quarterly)$0.31
Price vs S&P 500 (YTD)60.69%
Gross Margin (TTM)56.56%
Net Profit Margin (TTM)-9.64%
EPS (TTM)$-0.76
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.76
Revenue Growth (5Y)-2.87%
EPS (Annual)$-0.76
ROI (Annual)-7.58%
Gross Margin (Annual)56.56%
Net Profit Margin (5Y Avg)-22.61%
Cash / Share (Quarterly)$4.14
Revenue Growth QoQ (YoY)0.04%
ROA (Last FY)-5.72%
Revenue Growth TTM (YoY)-25.68%
EBITD / Share (TTM)$-0.40
ROE (5Y Avg)-17.39%
Operating Margin (TTM)-9.80%
Cash Flow / Share (Annual)$0.31
P/B Ratio1.49x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.39x
Net Interest Coverage (TTM)13.00x
ROA (TTM)-5.74%
EV / EBITDA (TTM)64.04x
EPS Incl Extra (Annual)$-0.76
Current Ratio (Annual)4.72x
Quick Ratio (Quarterly)3.71x
3-Month Avg Trading Volume0.15M
52-Week Price Return12.84%
EV / Free Cash Flow (Annual)35.82x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10.21
P/S Ratio (Annual)1.89x
Asset Turnover (Annual)0.59x
52-Week High$16.24
Operating Margin (5Y Avg)-4.84%
EPS Excl Extra (Annual)$-0.76
CapEx CAGR (5Y)33.17%
Tangible BV CAGR (5Y)-4.78%
26-Week Price Return73.85%
Quick Ratio (Annual)3.71x
13-Week Price Return66.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.72x
Enterprise Value$156.261
Revenue / Share Growth (5Y)-3.06%
Asset Turnover (TTM)0.60x
Book Value / Share Growth (5Y)-11.52%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.30x
Pretax Margin (Annual)-8.25%
Cash / Share (Annual)$4.14
3-Month Return Std Dev51.62%
Gross Margin (5Y Avg)57.20%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-46.37%
ROE (Last FY)-7.58%
Net Interest Coverage (Annual)-7.33x
EPS Basic Excl Extra (Annual)$-0.76
P/FCF (TTM)23.82x
Receivables Turnover (TTM)4.77x
EV / Free Cash Flow (TTM)35.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.76
Receivables Turnover (Annual)4.77x
ROI (TTM)-7.42%
P/S Ratio (TTM)1.89x
Pretax Margin (5Y Avg)-3.80%
Revenue / Share (Annual)$7.87
Tangible BV / Share (Annual)$10.21
Forward P/E49.19x
Free OCF CAGR (5Y)-17.54%
Price vs S&P 500 (52W)-21.79%
Year-to-Date Return64.62%
5-Day Price Return3.40%
EPS Normalized (Annual)$-0.76
ROA (5Y Avg)-13.43%
Net Profit Margin (Annual)-9.64%
Month-to-Date Return9.10%
Cash Flow / Share (TTM)$-0.69
EBITD / Share (Annual)$-0.40
Operating Margin (Annual)-9.80%
LT Debt / Equity (Annual)0.07x
P/CF (TTM)19.10x
ROI (5Y Avg)-17.39%
LT Debt / Equity (Quarterly)0.09x
EPS Basic Excl Extra (TTM)$-0.76
P/TBV (Quarterly)0.98x
P/B Ratio (Annual)0.97x
Inventory Turnover (TTM)2.30x
Pretax Margin (TTM)-8.25%
Book Value / Share (Annual)$10.33
Price vs S&P 500 (13W)63.62%
Beta0.35x
P/FCF (Annual)49.00x
Revenue / Share (TTM)$7.90
ROE (TTM)-7.42%
52-Week Low$7.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ANIKAnika Therapeutics Inc | 1.89x | -2.87% | 56.56% | -9.80% | $15.82 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Anika Therapeutics develops osteoarthritis pain management solutions using proprietary hyaluronic acid technology. The company's principal products—Orthovisc, Monovisc, and Cingal—are office-administered viscosupplement products marketed exclusively in the U.S. by Johnson & Johnson MedTech. Primary revenue is derived from the U.S. market, with additional contributions from OEM licensing and international operations.